A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response

Publication date

2016-01-18

Authors

Melo, C A
Léveillé, N
Rooijers, K
Wijchers, Patrick J
Geeven, G
Tal, A
Melo, S A
de Laat, WouterISNI 0000000388639337
Agami, R

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

Genome-wide chromatin studies identified the tumor suppressor p53 as both a promoter and an enhancer-binding transcription factor. As an enhancer factor, p53 can induce local production of enhancer RNAs, as well as transcriptional activation of distal neighboring genes. Beyond the regulation of protein-coding genes, p53 has the capacity to regulate long intergenic noncoding RNA molecules (lincRNAs); however, their importance to the p53 tumor suppressive function remains poorly characterized. Here, we identified and characterized a novel p53-bound intronic enhancer that controls the expression of its host, the lincRNA00475 (linc-475). We demonstrate the requirement of linc-475 for the proper induction of a p53-dependent cell cycle inhibitory response. We further confirm the functional importance of linc-475 in the maintenance of CDKN1A/p21 levels, a cell cycle inhibitor and a major p53 target gene, following p53 activation. Interestingly, loss of linc-475 reduced the binding of both p53 and RNA polymerase II (RNAPII) to the promoter of p21, attenuating its transcription rate following p53 activation. Altogether, our data suggest a direct role of p53-bound enhancer domains in the activation of lincRNAs required for an efficient p53 transcriptional response.Oncogene advance online publication, 18 January 2016; doi:10.1038/onc.2015.502.

Keywords

Taverne, Journal Article

Citation

Melo, C A, Léveillé, N, Rooijers, K, Wijchers, P J, Geeven, G, Tal, A, Melo, S A, de Laat, W & Agami, R 2016, 'A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response', Oncogene, vol. 35, pp. 4399–4406. https://doi.org/10.1038/onc.2015.502